ArticleVeterinary research2026
Residues Y142, I143, T146, Q206, S215, R228, G267, and M268 in the surface glycoprotein of FGV-like subgroup A avian leukosis virus are the key sites determining Tva receptor binding and infectivity.
Article in Veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Avian leukosis virus subgroup A (ALV-A) invades cells through the specific recognition of the cellular receptor Tva by its encoded surface glycoprotein gp85. Certain Fowl glioma-inducing virus (FGV) strains and their variants belong to ALV-A, but their gp85 proteins differ substantially from classical ALV-A strains. To identify the key residues in the gp85 of FGV-like ALV-A strain 2023ZW001 that determine Tva-binding affinity and infectivity, a strategy of substituting the corresponding gp85 residues between ALV-A 2023ZW001 and ALV-E ev-1 (which uses Tvb as its receptor) was adopted. A series of chimeric gp85 proteins for receptor binding assays were expressed, and multiple recombinant retroviral vectors RCASBP(ZW/ev-1)-EGFP/mCherry were constructed to transfect DF-1 cells for replication capacity analysis. The results showed that host range region 1 (hr1), host range region 2 (hr2), and variable region 3 (vr3) play a decisive role in mediating viral infection. Among these regions, residues 140-146 in hr1 and residues 267-273 in vr3 are the indispensable regions for 2023ZW001 to bind the receptor and mediate viral infection. Residues Y142, I143, and T146 in hr1; residues Q206, S215, and R228 in hr2; and as residues G267 and M268 in vr3 are the key sites determining Tva receptor binding and infectivity. This study indicated that hr1 and hr2 of the FGV-like ALV-A strain contain the major receptor interaction determinants, while vr3 also plays a key role in receptor-binding affinity and infectivity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.